Michaela Fleming

Robert Salata, MD, discusses the ARMS-I clinical trial that will enroll clinical staff caring for patients with COVID-19.

Wendy M. Bamberg, MD, the editor of Contagion®’s Emerging and Re-emerging Infections section, shares her thoughts on social distancing, managing suspect cases, and lessons we can learn about COVID-19.

Stay up to date on the latest coronavirus updates from Tuesday April 7th.

The CDC will produce a weekly report called COVIDView. The report will be updated each Friday with US-based surveillance information.

Catch up on the latest coronavirus news from April 6, 2020.

Check out the latest coronavirus news from April 3, 2020.

Check out the latest coronavirus news from April 2, 2020.

The goal of the program will be to quickly bring effective medical countermeasures to patients while also supporting research to assess the safety and efficacy of these therapies.

As of March 30th, 20 emergency use authorizations have been granted for COVID-19 diagnostics.

Erin K. McCreary, PharmD, BCPS, BCIDP, discusses emerging literature on potential therapies COVID-19 and how the infectious disease community can work together during this pandemic.

Stay on top of coronavirus news from March 24, 2020.

Stay on top of coronavirus developments from March 20, 2020.

The agency notes that they are working closely with industry officials to expedite efforts to develop countermeasures for COVID-19.

Stay on top of coronavirus developments from March 19, 2020.

According to Abbott, the systems can run high volumes of up to 470 tests in 24 hours.

Stay on top of coronavirus developments from March 18, 2020.

The trial will enroll 45 health adult participants between the ages of 18 to 55 years of age over a 6-week period. The first trial participant received the investigation vaccine, mRNA-1273, today.

Sanofi and Regeneron are launching a clinical trial program which will evaluate sarilumab (Kevzara) in patients who are hospitalized with severe coronavirus (COVID-19) infection.

New Jersey residents are being instructed to remain in their homes between the hours of 8pm and 5am in attempt to control the spread of COVID-19 in the Garden State.

Stay on top of coronavirus developments from March 13, 2020.

Contagion® spoke to Onyema Ogbuagu, MD, who presented the week 96 results from the DISCOVER study evaluating F/TAF and F/TDF.

There was a statistically significant difference in renal safety which favored F/TAF over F/TDF at Week 96.

The abstract authors report that both HIV viral load in plasma and proviral HIV DNA in CD4 cells have remained below levels of detection for up to 30 months.

“There are structural drivers that are impeding prevention and treatment among people who inject drugs,” Strathdee said in an interview with Contagion®.

New Week 96 data from the FLAIR study indicate that once-monthly injections of cabotegravir and rilpivirine remains non-inferior and safe when compared with the daily, oral 3-drug regimen of ABC/DTG/3TC.

A team of investigators hypothesized that prevalent syphilis infection in women with and without HIV may be a way to identify individuals who are at an elevated risk of a stillbirth over time.

Despite the high level of knowledge surrounding immediate initiation of ART, the practice is not yet the standard of care across clinics in NYC.

Investigators conducted 2 studies on intravenously administered GS-9722, 1 in HIV-negative participants and 1 in virally suppressed people with HIV.

Stay on top of coronavirus developments from March 6, 2020.

The influenza hospitalization rate for children and young adults has surpassed the rate documented during the second wave of the 2009 H1N1 pandemic.